Sulfadiazine is an approved antibiotic for treating meningococcal meningitis. For people with HIV it is most commonly used in combination with pyrimethamine (Daraprim) for treating Pneumocystis pneumonia (PCP) or toxoplasmosis.

It is the drug which causes the highest rate of allergic skin reactions: 20% of recipients can expect significant side-effects during a course of treatment.1


  1. Coopman SA et al. Cutaneous disease and drug reactions in HIV infection. N Engl J Med 328: 1670-1674, 1993

Community Consensus Statement on Access to HIV Treatment and its Use for Prevention

Together, we can make it happen

We can end HIV soon if people have equal access to HIV drugs as treatment and as PrEP, and have free choice over whether to take them.

Launched today, the Community Consensus Statement is a basic set of principles aimed at making sure that happens.

The Community Consensus Statement is a joint initiative of AVAC, EATG, MSMGF, GNP+, HIV i-Base, the International HIV/AIDS Alliance, ITPC and NAM/aidsmap

This content was checked for accuracy at the time it was written. It may have been superseded by more recent developments. NAM recommends checking whether this is the most current information when making decisions that may affect your health.

NAM’s information is intended to support, rather than replace, consultation with a healthcare professional. Talk to your doctor or another member of your healthcare team for advice tailored to your situation.